KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Common Equity (2016 - 2025)

Astrazeneca (AZN) has 3 years of Common Equity data on record, last reported at $48.7 billion in Q4 2025.

  • For Q4 2025, Common Equity rose 19.2% year-over-year to $48.7 billion; the TTM value through Dec 2025 reached $48.7 billion, up 19.2%, while the annual FY2025 figure was $48.7 billion, 19.2% up from the prior year.
  • Common Equity reached $48.7 billion in Q4 2025 per AZN's latest filing, up from $40.9 billion in the prior quarter.
  • Across five years, Common Equity topped out at $48.7 billion in Q4 2025 and bottomed at $39.2 billion in Q4 2023.
  • Average Common Equity over 3 years is $42.9 billion, with a median of $40.9 billion recorded in 2024.
  • Peak YoY movement for Common Equity: grew 4.35% in 2024, then grew 19.2% in 2025.
  • A 3-year view of Common Equity shows it stood at $39.2 billion in 2023, then rose by 4.35% to $40.9 billion in 2024, then rose by 19.2% to $48.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $48.7 billion in Q4 2025, $40.9 billion in Q4 2024, and $39.2 billion in Q4 2023.